Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.46 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.46 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.46 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.43 |
| ▸ | DDB1 known ✓ | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN known ✓ | Q96SW2 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29463791 | 1.00 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4008149 | 1.00 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL29979775 | 0.98 | SLC18A3 (0.50) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL169353 | 0.98 | SLC18A3 (0.50) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL10651872 | 0.91 | SLC18A3 (0.44) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3972091 | 0.89 | SLC18A3 (0.41) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL7471598 | 0.88 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL3921393 | 0.87 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL29889405 | 0.87 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL14868820 | 0.87 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023151575-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-113480534-B | Benzimidazole or azabenzimidazole-6-carboxylic acid compounds and application thereof | 广州必贝特医药股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-8741892-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20130143870-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| CN-102260272-A | Method for preparing irinotecan hydrochloride | — | 2011-11-30 | — | — | CN | disclosed |
| WO-2009081259-A1 | PHENOXY-PYRIDYL DERIVATIVES | PFIZER INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| EP-0966440-B1 | METHOD OF PRODUCTION AND METHOD OF SEPARATION OF 2,4'-DIPYRIDYL DERIVATIVES AND METHODS OF PRODUCTION OF BENZOXAZEPINE DERIVATIVES AND SALTS THEREOF | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-6624308-B2 | Cross coupling of 2-halopyridine and 4-halopyridine using nickel complex catalyst | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-09-23 | — | — | US | disclosed |
| US-20030125547-A1 | Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2003-07-03 | — | — | US | disclosed |
| CN-1107054-C | Preparation method, separation method and application of 2,4' -dipyridyl derivative | SUNTORY LTD (JP) | 2003-04-30 | — | — | CN | disclosed |
| US-6096884-A | CROSS COUPLING REACTION OF A 2-HALOPYRIDINE DERIVATIVE AND A 4-HALOPYRIDINE USING A NICKEL COMPLEX CATALYST | SUNTORY LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0966440-A1 | METHOD OF PRODUCTION AND METHOD OF SEPARATION OF 2,4'-DIPYRIDYL DERIVATIVES AND METHODS OF PRODUCTION OF BENZOXAZEPINE DERIVATIVES AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-12-29 | — | — | EP | disclosed |
| CN-1230950-A | Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof | SUNTORY LTD (JP) | 1999-10-06 | — | — | CN | disclosed |
| WO-1998052922-A1 | METHOD OF PRODUCTION AND METHOD OF SEPARATION OF 2,4'-DIPYRIDYL DERIVATIVES AND METHODS OF PRODUCTION OF BENZOXAZEPINE DERIVATIVES AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125547-A1 | Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof | WIZ, HELZ, HPD | SIGMAR1 735/4885HTR1A 3997/4885SLC6A2 1080/4885 |
| US-20130143870-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | SIGMAR1 148/4885HTR1A 113/4885SLC6A2 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.